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Purpose: To report a case of radiation-induced macular ischemia where vision and macular 
perfusion improved after hyperbaric oxygen (HBO) therapy.
Methods: A 62-year-old male patient developed radiation-induced macular ischemia after he 
was treated with radiation for brain glioma. The patient presented with best spectacle-corrected 
visual acuity (BSCVA) acuity of 20/400 in his right eye. Optical coherence tomography (OCT) 
showed central macular thickness of 468 µm. The patient received focal laser, intravitreal 
t  riamcinolone, and HBO therapy.
Results: The patient’s vision improved from 20/400 to 20/100 after focal laser and intravitreal 
triamcinolone. His central macular thickness improved from 468 µm to 132 µm. After receiving 
HBO therapy, his VA improved to 20/50 and fluorescein angiography showed improvement 
in macular perfusion.
Conclusion: HBO therapy improves macular perfusion in patients with radiation-induced 
macular ischemia.
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Stallard first described radiation retinopathy in 1933 in patients receiving ocular 
i  rradiation with radon seeds for retinoblastoma and retinal capillary hemangioma.1 
Radiation retinopathy is an occlusive microangiopathy resulting in tissue ischemia sec-
ondary to endothelial cell loss and capillary closure occurring after ionizing   radiation 
treatment. Radiation retinopathy has been seen after both radioactive plaque and 
e  xternal beam radiation for ocular and nonocular diseases. Radiotherapy has been a 
great advance in the treatment of life- and sight-threatening conditions. It is being used 
in increasing frequency for ocular and nonocular diseases, as a result of which cases of 
radiation retinopathy may become more prevalent. Usually the vision loss in r  adiation 
retinopathy is secondary to macular edema and subsequent ischemia, n  eovascular 
glaucoma, and radiation optic neuropathy. Currently, no definitive therapy is available 
for the treatment of radiation retinopathy. Kinyoun et al2 reported the first success-
ful treatment of radiation-induced macular edema with panretinal p  hotocoagulation, 
and at present this is the most widely-used treatment for radiation retinopathy. Other 
treatments like intravitreal triamcinolone and bevacizumab have been shown to be 
effective in treating radiation-induced macular edema.3,4 While the use of hyperbaric 
oxygen (HBO) therapy for radiation-induced optic neuropathy has been described, to 
date, its use for radiation-induced macular ischemia has not been described.5 Over the 
last two decades, animal studies, clinical trials, and well-validated clinical experience 
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have suggested the efficacy of HBO for many indications, and 
recently there has been a renewed interest in this field.
We report a 62-year-old Hispanic male who developed 
radiation-induced macular edema after he was treated with 
radiation for a brain glioma. The patient presented with best-
corrected visual acuity BC of 20/400 in his left eye and 20/25 
in his right eye. Optical coherence tomography (OCT) of his 
right eye showed a central macular thickness of 468 µm (Fig-
ure 1). One week after presentation, the patient received one 
session of focal laser, and six weeks after   initial p  resentation 
his visual acuity in his left eye remained unchanged. At that 
time, he received one injection of intravitreal   triamcinolone 
(4 mg). Three months after initial presentation, his vision 
improved from 20/400 to 20/100 and his foveal thickness 
reduced to 132 µm with complete resolution of the retinal 
fluid (Figure 2).
Three months after initial presentation, after receiving 
one session of focal laser, and one injection of intravitreal 
triamcinolone (IVT), the patient then received a total of 18 
HBO treatments over a one-month period (100% oxygen 
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Figure 2 (Left) OCT color retinal map (top) and thickness map (bottom) showing regression of central macular thickness to 132 µm. (Right) Horizontal line scan showing 
no intraretinal fluid or serous retinal detachment after treatment with focal laser and intravitreal injection of triamcinolone. BSCVA improved from 20/400 to 20/100.
Figure 1 (Left) Optical coherence tomography retinal color map (top) and thickness map (bottom) showing central macular thickness of 468 µm before any treatment. 
(Right) Horizontal line scan of macula showing intraretinal and subretinal fluid with large serous retinal detachment. At presentation, best spectacle-corrected visual acuity 
was 20/400.
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at two atmospheres for 90 minutes; two air breaks of 5 
minutes each). After undergoing HBO treatment, his visual 
acuity continued to improve to 20/50 with stable central 
macular thickness, though his macular perfusion showed 
little change as demonstrated by fluorescein angiography 
(Figure 3).
Though it is unclear in our patient if focal laser had any 
definite effect, intravitreal triamcinolone resulted in a marked 
improvement in macular thickness, returning it to normal, and 
improving vision from 20/400 to 20/100. After the patient 
received a series of HBO treatments, the vision improved 
further from 20/100 to 20/50, while the macular thickness 
on OCT remained stable. Fluorescein angiography demon-
strated some improvement in macular perfusion (Figure 3). 
  Considering that there was no macular edema seen on OCT 
at the time when patient began HBO therapy, we believe that 
the patient’s i  mprovement in visual acuity from 20/100 to 
20/50 was because of i  mprovement in the macular ischemia 
after he received HBO therapy. However, it is possible that the 
triamcinolone may have contributed to the effect seen with 
the HBO therapy.
Treatments like focal laser, intravitreal triamicinolone and 
intravitreal bevacizumab may help in reducing the   macular 
edema, as happened in our patient, but they really do not 
directly address the ischemic component of the c  ondition that 
permanently contributes to vision loss. There is a g  rowing 
interest in the use of HBO therapy in medicine in general, 
and in ophthalmology in particular. The conditions for 
which HBO therapy has shown clear scientific evidence are 
decompression sickness, arterial gas embolism, and severe 
carbon monoxide poisoning.6 It has also been shown to be 
useful as an adjunctive therapy in prevention and treatment 
of radiation-induced bone injury (osteoradionecrosis), skin 
grafts and flap healing, and chlostridial myonecrosis. There 
is some suggestive scientific evidence of beneficial effects of 
HBO therapy in other conditions like refractive osteomyelitis, 
acute traumatic ischemic injury, radiation-induced cystitis, 
and prolonged failure of wound healing such as in diabetic 
foot ulcers.
HBO therapy has also been shown to be beneficial 
in o  cclusive vasculopathies such as central retinal artery 
  occlusion, branch retinal artery occlusion, and cystoid   macular 
edema secondary to retinal vein occlusions.5   During HBO 
therapy, 100% oxygen is applied at a very high   pressure two- 
to three-fold of that found in the air at sea level. The higher 
concentration and pressure of oxygen increases the amount 
of oxygen dissolved in the plasma, and also increases the 
t  issue gradient to transfer oxygen into the tissue. The r  esultant 
hyperoxia increases the tissue’s   consumption of o  xygen, 
and initiates cellular and vascular repair mechanisms.7–9 
HBO therapy affects many of the   components involved in 
ischemia-reperfusion injury, including p  olymorphonuclear 
leukocyte function, endothelial c  ellular adhesion molecule 
expression, nitric oxide p  roduction, nitric oxide synthase 
expression, cellular energetic, lipid   peroxidation, and 
  microvascular blood flow.5
Considering that the pathophysiology of radiation-induced 
macular ischemia is similar to other occlusive   vasculopathies 
in which HBO therapy has been shown to be beneficial, 
we believe that HBO therapy in radiation-induced   macular 
i  schemia may be helpful. Further evaluation of HBO 
  treatment in patients with radiation-induced macular 
  ischemia is warranted.
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Figure 3 Late phase fluorescein angiography, (Left) showing collaterals and ischemia of the macula before HBO therapy. (Right) showing improvement of collaterals and 
ischemia after HBO therapy. BSCVA improved from 20/100 to 20/50 after the HBO therapy.
Abbreviations: BSCVA, best spectacle-corrected visual acuity; HBO, hyperbaric oxygen.
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